CAREERS We are pushing further, discovering more, and redefining treatment expectations for patients and providers. But as passionate as we are about our work, we’re equally passionate about doing everything with integrity, ethics, and inclusion. Careers We live, breathe, and sleep scientific innovation. It’s the “why” behind everything we do. If you are driven by […]
CLINICAL TRIALS Pancreatic Cancer About 84,000 people in the U.S. are living with pancreatic cancer, based on a 2018 estimate. In the U.S., only about 10% of patients live for at least 5 years after being diagnosed with pancreatic cancer, and about 48,000 patients were predicted to die of pancreatic cancer in 2021. Pancreatic cancer
OUR SCIENCE THE TARGET GSK-3β has long been an attractive target in cancer therapy, but previous drug candidates developed to inhibit GSK-3β have been limited by poor pharmaceutical characteristics and/or significant adverse effects in patients, limiting their clinical utility. The Function of GSK-3β GSK-3β is an enzyme that regulates a number of intersecting biological pathways
THE PASSION TO PURSUE MORE Who we are Actuate aims to give patients with hard-to-treat cancers the opportunity to live longer and better with the potential capacity to slow, stop, or shrink tumors, with minimal adverse effects. Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitor), targets multiple molecular pathways in cancer that are involved in promoting
PRIVACY NOTICE Last updated and effective as of December 20, 2023. This Privacy Notice explains the practices that Actuate Therapeutics, Inc. (“Actuate”, “we”, “us”, “our”) follows in connection with the personal data that we collect through this website, when you contact us directly and through our research. We may change this Privacy Notice at any
Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity of GSK-3β inhibitors CHICAGO, IL and FORT WORTH, TX – March 1, 2022 – Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient
Elraglusib will be combined with FOLFIRINOX alone or with Losartan in multi-centerPhase 2 clinical study initiated at Massachusetts General Hospital, Fred Hutchinson CancerResearch Center, University of Colorado, Denver, and Johns Hopkins University with studyfunding provided by the Lustgarten Foundation for Pancreatic Cancer Research CHICAGO, IL and FORT WORTH, TX – February 7, 2022 – Actuate
